Alexander Melamed1, Emily M Hinchcliff2, Joel T Clemmer2, Amy J Bregar2, Shitanshu Uppal3, Ian Bostock4, John O Schorge2, Marcela G Del Carmen2, J Alejandro Rauh-Hain2. 1. Division of Gynecologic Oncology, Vincent Obstetrics and Gynecology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States. Electronic address: amelamed@partners.org. 2. Division of Gynecologic Oncology, Vincent Obstetrics and Gynecology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States. 3. Division of Gynecologic Oncology, Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI, United States. 4. Department of Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, NH.
Abstract
OBJECTIVE: Neoadjuvant chemotherapy and interval debulking surgery for the treatment of advanced ovarian cancer has remained controversial, despite the publication of two randomized trials comparing this modality with primary cytoreductive surgery. This study describes temporal trends in the utilization of neoadjuvant chemotherapy and interval debulking surgery in clinical practice in the United States. METHODS: We completed a time trend analysis of the National Cancer Data Base. We identified women with stage IIIC and IV epithelial ovarian cancer diagnosed between 2004 and 2013. We categorized subjects as having undergone one of four treatment modalities: primary cytoreductive surgery followed by adjuvant chemotherapy, neoadjuvant chemotherapy followed by interval debulking surgery, surgery only, and chemotherapy only. Temporal trends in the frequency of treatment modalities were evaluated using Joinpoint regression, and χ2 tests. RESULTS: We identified 40,694 women meeting inclusion criteria, of whom 27,032 (66.4%) underwent primary cytoreductive surgery and adjuvant chemotherapy, 5429 (13.3%) received neoadjuvant chemotherapy and interval surgery, 5844 (15.4%) had surgery only, and 2389 (5.9%) received chemotherapy only. The proportion of women receiving neoadjuvant chemotherapy and surgery increased from 8.6% to 22.6% between 2004 and 2013 (p<0.001), and adoption of this treatment modality occurred primarily after 2007 (95%CI 2006-2009; p=0.001). During this period, the proportion of women who received primary cytoreductive surgery and chemotherapy declined from 68.1% to 60.8% (p<0.001), and the proportion who underwent surgery only declined from 17.8% to 9.9% (p<0.001). CONCLUSION: Between 2004 and 2013 the frequency of neoadjuvant chemotherapy and interval surgery increased significantly in the United States.
OBJECTIVE: Neoadjuvant chemotherapy and interval debulking surgery for the treatment of advanced ovarian cancer has remained controversial, despite the publication of two randomized trials comparing this modality with primary cytoreductive surgery. This study describes temporal trends in the utilization of neoadjuvant chemotherapy and interval debulking surgery in clinical practice in the United States. METHODS: We completed a time trend analysis of the National Cancer Data Base. We identified women with stage IIIC and IV epithelial ovarian cancer diagnosed between 2004 and 2013. We categorized subjects as having undergone one of four treatment modalities: primary cytoreductive surgery followed by adjuvant chemotherapy, neoadjuvant chemotherapy followed by interval debulking surgery, surgery only, and chemotherapy only. Temporal trends in the frequency of treatment modalities were evaluated using Joinpoint regression, and χ2 tests. RESULTS: We identified 40,694 women meeting inclusion criteria, of whom 27,032 (66.4%) underwent primary cytoreductive surgery and adjuvant chemotherapy, 5429 (13.3%) received neoadjuvant chemotherapy and interval surgery, 5844 (15.4%) had surgery only, and 2389 (5.9%) received chemotherapy only. The proportion of women receiving neoadjuvant chemotherapy and surgery increased from 8.6% to 22.6% between 2004 and 2013 (p<0.001), and adoption of this treatment modality occurred primarily after 2007 (95%CI 2006-2009; p=0.001). During this period, the proportion of women who received primary cytoreductive surgery and chemotherapy declined from 68.1% to 60.8% (p<0.001), and the proportion who underwent surgery only declined from 17.8% to 9.9% (p<0.001). CONCLUSION: Between 2004 and 2013 the frequency of neoadjuvant chemotherapy and interval surgery increased significantly in the United States.
Authors: Nathaniel L Jones; Ling Chen; Sudeshna Chatterjee; Ana I Tergas; William M Burke; June Y Hou; Cande V Ananth; Alfred I Neugut; Dawn L Hershman; Jason D Wright Journal: Int J Gynecol Cancer Date: 2018-01 Impact factor: 3.437
Authors: Joseph A Dottino; Weiguo He; Charlotte C Sun; Hui Zhao; Shuangshuang Fu; Jose Alejandro Rauh-Hain; Rudy S Suidan; Karen H Lu; Sharon H Giordano; Larissa A Meyer Journal: Int J Gynecol Cancer Date: 2020-07-02 Impact factor: 3.437
Authors: Roni Nitecki; Jose Alejandro Rauh-Hain; Alexander Melamed; Giovanni Scambia; Rene Pareja; Robert L Coleman; Pedro T Ramirez; Anna Fagotti Journal: Int J Gynecol Cancer Date: 2020-07-20 Impact factor: 3.437
Authors: Jennifer Anne Doherty; Lauren Cole Peres; Chen Wang; Gregory P Way; Casey S Greene; Joellen M Schildkraut Journal: Curr Epidemiol Rep Date: 2017-07-10
Authors: Nicole D Fleming; Shannon N Westin; J Alejandro Rauh-Hain; Pamela T Soliman; Bryan M Fellman; Robert L Coleman; Larissa A Meyer; Aaron Shafer; Lauren P Cobb; Amir Jazaeri; Karen H Lu; Anil K Sood Journal: Gynecol Oncol Date: 2021-04-07 Impact factor: 5.304
Authors: Benjamin B Albright; Karen A Monuszko; Samantha J Kaplan; Brittany A Davidson; Haley A Moss; Allan B Huang; Alexander Melamed; Jason D Wright; Laura J Havrilesky; Rebecca A Previs Journal: Am J Obstet Gynecol Date: 2021-05-04 Impact factor: 10.693
Authors: Ellen L Goode; Matthew S Block; Kimberly R Kalli; Robert A Vierkant; Wenqian Chen; Zachary C Fogarty; Aleksandra Gentry-Maharaj; Aleksandra Tołoczko; Alexander Hein; Aliecia L Bouligny; Allan Jensen; Ana Osorio; Andreas Hartkopf; Andy Ryan; Anita Chudecka-Głaz; Anthony M Magliocco; Arndt Hartmann; Audrey Y Jung; Bo Gao; Brenda Y Hernandez; Brooke L Fridley; Bryan M McCauley; Catherine J Kennedy; Chen Wang; Chloe Karpinskyj; Christiani B de Sousa; Daniel G Tiezzi; David L Wachter; Esther Herpel; Florin Andrei Taran; Francesmary Modugno; Gregg Nelson; Jan Lubiński; Janusz Menkiszak; Jennifer Alsop; Jenny Lester; Jesús García-Donas; Jill Nation; José Palacios; Joseph H Rothstein; Joseph L Kelley; Jurandyr M de Andrade; Luis Robles-Díaz; Maria P Intermaggio; Martin Widschwendter; Matthias W Beckmann; Matthias Ruebner; Mercedes Jimenez-Linan; Naveena Singh; Oleg Oszurek; Paul R Harnett; Peter F Rambau; Peter Sinn; Philipp Wagner; Prafull Ghatage; Raghwa Sharma; Robert P Edwards; Roberta B Ness; Sandra Orsulic; Sara Y Brucker; Sharon E Johnatty; Teri A Longacre; Eilber Ursula; Valerie McGuire; Weiva Sieh; Yanina Natanzon; Zheng Li; Alice S Whittemore; deFazio Anna; Annette Staebler; Beth Y Karlan; Blake Gilks; David D Bowtell; Estrid Høgdall; Francisco J Candido dos Reis; Helen Steed; Ian G Campbell; Jacek Gronwald; Javier Benítez; Jennifer M Koziak; Jenny Chang-Claude; Kirsten B Moysich; Linda E Kelemen; Linda S Cook; Marc T Goodman; María José García; Peter A Fasching; Stefan Kommoss; Suha Deen; Susanne K Kjaer; Usha Menon; James D Brenton; Paul DP Pharoah; Georgia Chenevix-Trench; David G Huntsman; Stacey J Winham; Martin Köbel; Susan J Ramus Journal: JAMA Oncol Date: 2017-12-01 Impact factor: 33.006
Authors: Alexander Melamed; Günther Fink; Alexi A Wright; Nancy L Keating; Allison A Gockley; Marcela G Del Carmen; John O Schorge; J Alejandro Rauh-Hain Journal: BMJ Date: 2018-01-03